Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 120

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 120
---
 of goods sold is primarily driven by the increase in net product sales over the same periods. Despite the increase, the Gross Margin % increased significantly from (39.09%) for the three months ended September 30, 2023 to 17.45% for the three months ended September 30, 2024. This is primarily attributable to the fixed part of cost of goods. As the sales volume has increased, the gross margin has improved as the variable cost of goods of each unit sold is substantially less than the sales price. Other Operating Revenues

|                   | Consolidated Statements of Operations Data: | Three Months Ended 
 September 30,      |   2024 |     |   |   2023 |     |   | $ Change |   |     |     | % Change |    |
|:------------------|:--------------------------------------------|:-------------------|-------:|:----|:--|-------:|:----|:--|:---------|:--|:----|:----|:---------|:---|
| Research Revenues |                                             | $                  | 12,818 |     | $ | 75,566 |     | $ | (62,748  | ) |     |     | (83.04   | )% |

The research revenues earned by us were $12,818 for the three months ended September 30, 2024, as compared to $75,566 for the three months ended September 30, 2023. Our research revenues for the three months ended September 30, 2023 consist entirely of projected research revenues from the Australian Tax Authority for research activities conducted in Australia. For the three months ended September 30, 2024, our research revenues relate primarily to initial funding earned from the new USAMMDA contract we were awarded in July 2024 to facilitate commercial validation of a new bottle and replacement blister packaging of Arakoda. Operating Expenses

|                                     | Consolidated Statements of Operations Data: | Three Months Ended 
 September 30,      |      2024 |     |   |      2023 |     |   | $ Change |   |     |     | % Change |   |
|:------------------------------------|:--------------------------------------------|:-------------------|----------:|:----|:--|----------:|:----|:--|---------:|:--|:----|:----|---------:|:--|
| Research and Development            |                                             | $                  |